Table 2.
Tumor type, stage at the time of treatment, treatment performed, survival, and follow-up data for each dog.
| Dog | Tumor type (if available) | Known or suspected metastatic disease pre-treatment? (Y or N) | Local treatment modality: SBRT (stereotactic body radiation therapy), PRT (palliative radiation therapy), ulnectomy | Adjuvant chemotherapy protocols (agent and number of injectable administrations if known) | Post-local treatment survival or follow-up time (days) | Time at death (D) or last follow-up (LFU) |
|---|---|---|---|---|---|---|
| 1 | Osteosarcoma | N | SBRT | Carboplatin × 3 | 66 | D |
| 2 | Osteosarcoma | N | SBRT | Carboplatin × 3 | 132 | D |
| 3 | Y | PRT | Cyclophosphamide | 134 | D | |
| 4 | Osteosarcoma | N | SBRT | Carboplatin × 2 | 158 | D |
| 5 | Chondrosarcoma | Y | SBRT | Toceranib | 199 | D |
| 6 | Sarcoma | N | SBRT | Carboplatin × 3, doxorubicin × 1, cyclophosphamide, toceranib, masitinib | 193 | D |
| 7 | Osteosarcoma | N | SBRT | Carboplatin × 6 | 313 | D |
| 8 | Y | PRT | N/A | 132 | D | |
| 9 | Osteosarcoma | Y | PRT | N/A | 108 | D |
| 10 | Osteosarcoma | N | PRT | N/A | 382 | D |
| 11 | Osteosarcoma | N | SBRT | Carboplatin × 2 | 227 | D |
| 12 | Y | SBRT | Carboplatin × 4 | 116 | D | |
| 13 | Y | PRT | Melphalan, doxorubicin | 14 | D | |
| 14 | N | PRT | N/A | 48 | D | |
| 15 | Y | SBRT | Carboplatin, doxorubicin, toceranib | 200 | D | |
| 16 | Osteosarcoma | N | PRT | N/A | 75 | D |
| 17 | Chondrosarcoma | N | PRT | N/A | 140 | D |
| 18 | Osteosarcoma | Y | PRT | Toceranib, doxorubicin | 109 | D |
| 19 | Sarcoma | N | SBRT | Carboplatin | 382 | D |
| 20 | Y | PRT | Carboplatin | 225 | D | |
| 21 | Y | PRT | Mitoxantrone, carboplatin, doxorubicin | 148 | LFU | |
| 22 | Sarcoma | N | SBRT | Carboplatin × 6 | 320 | D |
| 23 | Osteosarcoma | N | SBRT | Doxorubicin × 1, carboplatin × 3 | 117 | D |
| 24 | Osteosarcoma | N | PRT | N/A | 317 | LFU |
| 25 | Osteosarcoma | N | Ulnectomy | Carboplatin × 3, doxorubicin × 3 | 1,045 | D |
| 26 | Osteosarcoma | N | Ulnectomy | Carboplatin × 4 | 470 | D |
| 27 | Osteosarcoma | N | Ulnectomy | Carboplatin × 2 | 63 | D |
| 28 | Osteosarcoma | N | Ulnectomy | Carboplatin × 6, doxorubicin × 7 (30 mg/m2 × 4 and 10 mg/m2 × 3), lomustine × 2 | 626 | D |
| 29 | Osteosarcoma | N | Ulnectomy | Carboplatin × 4 | 1,324 | D |
| 30 | Osteosarcoma | N | Ulnectomy | Carboplatin × 6 | 392 | D |
| 31 | Osteosarcoma | N | Ulnectomy | Carboplatin × 6 | 198 | D |
| 32 | Osteosarcoma | N | Ulnectomy | Carboplatin × 4 | 267 | D |
| 33 | Osteosarcoma | N | Ulnectomy | Carboplatin × 4 | 90 | LFU |
| 34 | Osteosarcoma | N | Ulnectomy | Doxorubicin × 3 | 68 | D |
| 35 | Osteosarcoma | N | Ulnectomy | N/A | 86 | D |
| 36 | Osteosarcoma | N | Ulnectomy | N/A | 132 | D |
| 37 | Osteosarcoma | Y | Ulnectomy | N/A | 70 | D |
| 38 | Osteosarcoma | N | Ulnectomy | Carboplatin × 4 | 204 | D |
| 39 | Osteosarcoma | Y | Ulnectomy | Carboplatin × 2, toceranib | 477 | LFU |
| 40 | Osteosarcoma | N | Ulnectomy | Carboplatin × 2 | 66 | LFU |